Mental or Behavioral Dysfunction – Page 4

RFK Jr. Dodges Vaccine-Autism Questions in Senate Confirmation Responses

7 months ago talkbio0Tagged Autistic Disorder, CHARGE Syndrome, Confirmation, Hearings, Misinformation, Response process, Robert F. Kennedy, Secretary Nomination, Senate, Vaccines, Written - Consent Mode

Robert F. Kennedy Jr., HHS Secretary nomination, vaccine misinformation, autism, Senate confirmation hearings, written responses

FDA Approves Monthly Maintenance Dosing for Eisai and Biogen’s Alzheimer’s Drug Leqembi

7 months ago talkbio0Tagged Alzheimer 's disease, amyloid-beta, Approved, Biogen, dosing, Eisai, Leqembi, Maintenance, Mental deterioration, monthly, United States Food and Drug Administration

Leqembi, Alzheimer’s disease, FDA approval, monthly maintenance dosing, Eisai, Biogen, amyloid-beta, cognitive decline

Sage Therapeutics Rejects Biogen’s Acquisition Bid, Initiates Strategic Review

8 months ago talkbio0Tagged Acquisition, Biogen, Depression, Postpartum, Drug Industry, M&A, strategic alternatives, Zurzuvae

Sage Therapeutics, Biogen, acquisition rejection, strategic alternatives, ZURZUVAE, postpartum depression, pharmaceutical industry, M&A

Sage Therapeutics Rejects Biogen’s Acquisition Proposal, Remains Open to Future Deals

8 months ago talkbio0Tagged Acquisition, Biogen, Depression, Postpartum, Neurodevelopmental Disorders, Neuropsychiatry, proposal - intent, Zurzuvae

Sage Therapeutics, Biogen, Acquisition Proposal, Postpartum Depression, ZURZUVAE, Neurodevelopmental Disorders, Neuropsychiatry

Johnson & Johnson’s Darzalex and Spravato Achieve Milestones: Darzalex Leads Sales, Spravato Surpasses $1 Billion Revenue

8 months ago talkbio0Tagged Darzalex, Johnson and Johnson, Mental Depression, Multiple Myeloma, Pharmaceutical Sales, Revenue Milestones, Spravato

Johnson & Johnson, Darzalex, Spravato, Pharmaceutical Sales, Multiple Myeloma, Depression Treatment, Revenue Milestones

J&J’s Spravato Surpasses $1 Billion in Revenue for 2024

8 months ago talkbio0Tagged 2024, J&J, Mental Depression, Nasal Spray, Spravato

J&J, Spravato, revenue, 2024, depression treatment, nasal spray

Boehringer Ingelheim’s Iclepertin Fails to Meet Primary and Secondary Endpoints in Phase III Schizophrenia Trials

8 months ago talkbio0Tagged Boehringer Ingelheim, CONNEX, Iclepertin, Impaired cognition, Phase 3 Clinical Trials, Programs - Publication Format, Schizophrenia

Boehringer Ingelheim, iclepertin, schizophrenia, Phase III trials, cognitive impairment, CONNEX program

Johnson & Johnson Acquires Intra-Cellular Therapies for $14.6 Billion, Bolstering Neuroscience Portfolio

8 months ago talkbio0Tagged Acquisition, Caplyta, Depression, Bipolar, Intra-Cellular Therapies, Johnson and Johnson, Lumateperone, Neuroscience discipline, Schizophrenia

Johnson & Johnson, Intra-Cellular Therapies, Acquisition, Neuroscience, CAPLYTA, Lumateperone, Bipolar Depression, Schizophrenia, Major Depressive Disorder

Biogen Proposes Acquisition of Sage Therapeutics in $442 Million Deal

8 months ago talkbio0Tagged Acquisition, Biogen, Depression, Postpartum, Depressive disorder, Neurology speciality, zuranolone

Biogen, Sage Therapeutics, acquisition, neuro biotech, zuranolone, postpartum depression, major depressive disorder

Johnson & Johnson Acquires Intra-Cellular Therapies for $14.6 Billion, Expanding Neuroscience Portfolio

8 months ago talkbio0Tagged Acquisition, Caplyta, Depression, Bipolar, Intra-Cellular Therapies, Johnson and Johnson, Lumateperone, Neuroscience discipline, Schizophrenia

Johnson & Johnson, Intra-Cellular Therapies, Acquisition, Neuroscience, Caplyta, Lumateperone, Schizophrenia, Bipolar Depression, Major Depressive Disorder